From Active Molecules to Approved Drugs: What Are the Druggability Challenges in New Drug Development?

In the field of drug development, discovering a molecule with therapeutic potential is only the beginning of a long journey.

Many people assume that if a compound can effectively inhibit a disease-related target in laboratory experiments or demonstrate strong activity in cell-based assays, it has a good chance of becoming a blockbuster drug in the future.

However, the reality is far more complex. It is estimated that more than 90% of drug candidates ultimately fail to reach the market, with many failures occurring even before entering human clinical trials.

Therefore, in this article, DengYueMed analyzes the key druggability challenges in the journey from active molecules to approved medicines.

What Is Druggability?

Druggability refers to the potential of a candidate molecule to be successfully developed into a safe, effective, and commercially viable drug.

An ideal drug must not only demonstrate strong pharmacological activity but also meet several critical requirements, including:

● Sufficient efficacy

● Good safety profile

● Appropriate pharmacokinetic properties

● Stable manufacturing process

● Acceptable cost and market potentialTherefore, “active” does not necessarily mean “druggable.”

Many molecules can kill cancer cells, inhibit viral replication, or regulate specific biological targets in laboratory settings, but are ultimately eliminated from development pipelines because they fail to meet druggability requirements.

Challenge 1: Poor Oral Bioavailability

Oral administration is currently one of the most common and patient-friendly routes of drug delivery.

However, achieving good oral bioavailability is not easy for many candidate drugs.

Oral bioavailability refers to the proportion of a drug that reaches systemic circulation after oral administration and exerts its therapeutic effect.

Even a highly potent molecule may have poor oral performance due to the following reasons:

Poor Solubility

A drug must first dissolve in gastrointestinal fluids.

If a compound has low solubility, it cannot be sufficiently released in the body and therefore cannot be effectively absorbed.

Many innovative drug development programs have been terminated or required structural optimization due to solubility issues.

Poor Intestinal Absorption

A drug must pass through the intestinal epithelial cells to enter the bloodstream.

Some molecules are too large, too polar, or insufficiently lipophilic, resulting in extremely low absorption efficiency.

This is also a major reason why many biologics are difficult to develop as oral formulations.

First-Pass Effect

Even if a drug is successfully absorbed, it may be rapidly metabolized in the liver before reaching systemic circulation.

This phenomenon is known as the first-pass effect.

Severe first-pass metabolism can result in significant loss of active drug before it exerts its effect in the body.

Challenge 2: Poor Pharmacokinetic Properties

Pharmacokinetics (PK) describes how a drug is absorbed, distributed, metabolized, and excreted in the human body.

Researchers typically focus on the following key parameters:

● Absorption rate

● Half-life

● Volume of distribution

● Clearance rate

● Exposure levelIf a drug is metabolized too quickly, patients may require frequent dosing.

If it is metabolized too slowly, it may increase the risk of toxicity.

Even with strong laboratory efficacy, poor pharmacokinetic properties alone can lead to development failure.

Challenge 3: Safety Issues

Safety is one of the most critical evaluation criteria in drug development.

Many candidate drugs show promising results in cell and animal studies but later cause severe adverse effects in humans.

Common issues include:

● Hepatotoxicity

● Cardiotoxicity

● Nephrotoxicity

● Neurotoxicity

● Immune-related adverse effectsIn pharmaceutical development history, a large number of programs have been terminated due to safety concerns.

For regulatory authorities, while efficacy is important, safety remains the primary requirement for approval.

Challenge 4: Stability and Formulation Development Difficulties

Candidate molecules must not only be effective but also stable during production, storage, and transportation.

Some compounds may face:

● Light instability

● Thermal degradation

● Moisture sensitivity

● Loss of activity during long-term storageIn addition, formulation development must address several key questions:

● How to improve solubility?

● How to enhance absorption?

● How to extend duration of action?

● How to reduce dosing frequency?These challenges directly impact the market competitiveness of the final product.

Challenge 5: Discrepancy Between Preclinical and Clinical Results

A common situation in drug development is that a compound shows excellent results in the laboratory but performs poorly in human clinical trials.

This is mainly due to the significant differences between experimental models and real human physiology.

For example:

● More complex tumor microenvironments

● Genetic variability among patients

● Unpredictable immune system responses

● Incompletely understood disease mechanismsTherefore, a molecule that can achieve 100% inhibition in cell-based experiments may not necessarily show the same effectiveness in patients.

This is one of the major reasons for the high failure rate in clinical trials.

Emerging Technologies Improving Druggability

With continuous advances in drug development technologies, more innovative approaches are helping researchers overcome druggability challenges.

1. AI-Assisted Drug Design

Artificial intelligence can predict pharmacokinetic properties and potential toxicity, allowing early identification of risks.

2. Advanced Formulation Technologies

Nanoparticles, liposomes, and solid dispersions are improving the oral bioavailability of poorly soluble drugs.

3. Computer-Aided Screening

Research teams can evaluate thousands of candidate molecules early in development to reduce late-stage failure risk.

These technologies are significantly improving the efficiency of modern drug discovery.

Conclusion

The journey from discovering an active molecule to successfully developing an approved drug involves far more than simply confirming biological efficacy.

Oral bioavailability, pharmacokinetics, safety, stability, and clinical performance collectively determine whether a candidate molecule can ultimately reach the market.

In modern drug development, druggability assessment has become a critical factor influencing project success rates. For innovative pharmaceutical companies, identifying and addressing druggability challenges early can significantly shorten development timelines, reduce failure risks, and ultimately bring more innovative therapies to patients.

Global pharmaceutical distributor DengYueMed will continue to share content on drug development, innovative therapies, rational drug use, and global pharmaceutical market trends, providing international clients with drug supply information, market insights, and industry perspectives.